Kimia Biosciences Ltd

Kimia Biosciences Ltd has announced the closure of its trading window for dealing in the company's equity shares. This closure is effective from July 1, 2026, and will continue until 48 hours after the declaration of the unaudited financial results for the quarter ending June 30, 2026. The measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be closed for all promoters, directors, designated persons, and their immediate relatives. The company will separately announce the date of the Board of Directors' meeting to consider these financial results.

Kimia Biosciences Ltd. approved its audited standalone financial results for the financial year ended March 31, 2026, during a board meeting held on May 29, 2026. The results, along with the Independent Auditor’s Report, were reviewed and taken on record by the Board of Directors. The meeting commenced at 3:55 p.m. and concluded at 4:35 p.m. The auditor's report indicates a true and fair view of the company's state of affairs, profit, other comprehensive income, changes in equity, and cash flows for the specified period.

Kimia Biosciences Ltd has announced a Board of Directors meeting scheduled for May 29, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The trading window, which closed on April 1, 2026, will remain closed until 48 hours after the declaration of the financial results. The information will be available on the company's website.

Kimia Biosciences Ltd has announced the appointment of Mr. Mani Jain as its new Chief Financial Officer (CFO) and Key Managerial Personnel (KMP), effective April 27, 2026. The Board of Directors approved this appointment at their meeting held on the same date. Mr. Jain brings over 28 years of extensive experience in finance, accounts, treasury, budgeting, taxation, audits, and strategic financial management. His background includes senior leadership roles, fundraising, project finance, internal controls, and statutory compliances. The company confirmed that Mr. Jain is not related to any existing director and is not debarred by any regulatory authority.

Kimia Biosciences Ltd announced significant management changes following a Board Meeting on April 18, 2026. Ms. Richa Gupta ceased as an Independent Director with effect from April 14, 2026, upon completion of her second consecutive term/maximum tenure. Concurrently, Mr. Amulya Kumar Nayak (DIN: 11667557) was appointed as an Additional Director (Non-Executive, Non-Independent Category) from April 18, 2026, subject to shareholder approval. The Board also approved a modification in the re-appointment terms for Mr. Sameer Goel, Managing Director, making him liable to retire by rotation. Consequently, Board Committees were reconstituted with immediate effect.

Kimia Biosciences Ltd has appointed two new Additional Non-Executive Independent Directors, Mr. Avinash Prabhat and Ms. Reema Goyal, with a term of five years, subject to shareholder approval. The company has also reconstituted its Committees, including the Audit Committee, Nomination & Remuneration Committee, Stakeholders Relationship Committee, and Corporate Social Responsibility Committee. The changes are in compliance with the SEBI Listing Regulations and SEBI Master Circular.

Kimia Biosciences Ltd has announced the closure of its trading window for dealing in the shares of the company. This closure is in accordance with SEBI (Prohibition of Insider Trading), Regulations, 2015. The trading window will remain closed from 1st April, 2026 till 48 hours after the declaration of Audited Financial Results for the quarter and financial year ending 31st March, 2026. The date of the meeting of the Board of Directors to approve the Audited Financial Results for the quarter and financial year ending 31st March, 2026 will be informed in due course. Promoters, Directors, Connected Persons, Designated Persons of the company and their immediate relatives are advised not to trade in the shares of the company during the aforesaid period of closure of trading window.

Kimia Biosciences Ltd announced the resignation of Mr. Kaku Vijaya Shekhar Reddy, Additional Director (in the category of Executive Director), with effect from February 18, 2026. The company has accepted his resignation, which came into effect from the closure of business hours on February 19, 2026. The resignation was due to Mr. Reddy's personal reasons.

Kimia Biosciences Ltd has announced its financial results for the quarter and nine months ended on 31st December 2025. The company's revenue from operations stands at 3,010.06 lakhs for the quarter and 8,067.70 lakhs for the nine months ended on 31st December 2025. The Board has approved the re-appointment of Mr. Sameer Goel as Managing Director for a further period of five years. A postal ballot notice has been approved to seek approval from shareholders for the regularisation of Mr. Kaku Vijaya Shekhar Reddy as Whole time Director and the re-appointment of Mr. Sameer Goel as Managing Director.

Kimia Biosciences Limited, a company based at Gurgaon, Sohna Road, recently held a Board Meeting where several important decisions were made. The Board approved the un-audited financial results of the Company for the quarter and nine months ended on 31* December, 2025. The Managing Director, Mr. Sameer Goel, was re-appointed for a further period of five years. The Board also approved the re-appointment of Mr. Kaku Vijaya Shekhar Reddy as Whole time Director and the re-constitution of the Committees of the Board of Directors. The meeting commenced at 01:00 PM and concluded at 02:00 PM.